Douglas Sammon

Douglas Sammon

Auto-generated profile, based on publicly available information

Douglas Sammon

Department of Life Sciences, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
AJAbhishek A. Jalan
Abhishek A. Jalan
DSDouglas Sammon
Douglas Sammon
JHJeffrey D. Hartgerink
Jeffrey D. Hartgerink
PBPaul Brear
Paul Brear
KSKatherine Stott
Katherine Stott
RFRichard W. Farndale
Richard W. Farndale

13 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DSDouglas Sammon
Douglas Sammon
AKAnja Krueger
Anja Krueger
MBMarta Busse-Wicher
Marta Busse-Wicher
RMRhodri Marc Morgan
Rhodri Marc Morgan
SHStuart Haslam
Stuart Haslam
EHErhard Hohenester
Erhard Hohenester
Two major glycosaminoglycan types, heparan sulfate (HS) and chondroitin sulfate (CS), control many aspects of development and physiology in a type-specific manner. HS and CS are attached to core proteins via a common linker tetrasaccharide, but differ in their polymer backbones. How core proteins are specifically modified with HS or CS has been an enduring mystery. By reconstituting glycosaminoglycan biosynthesis in vitro, we establish that the CS-initiating N-acetylgalactosaminyltransferase CSGALNACT2 modifies all glycopeptide substrates equally, whereas the HS-initiating N-acetylglucosaminyltransferase EXTL3 is selective. Structure-function analysis reveals that acidic residues in the glycopeptide substrate and a basic exosite in EXTL3 are critical for specifying HS biosynthesis. Linker phosphorylation by the xylose kinase FAM20B accelerates linker synthesis and initiation of both HS and CS, but has no effect on the subsequent polymerisation of the backbone. Our results demonstrate that modification with CS occurs by default and must be overridden by EXTL3 to produce HS.

24 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DSDouglas Sammon
Douglas Sammon
EHErhard Hohenester
Erhard Hohenester
Birgit LeitingerBirgit Leitinger
Birgit Leitinger
Significance: Receptor tyrosine kinases (RTKs) are proteins on the surface of animal cells that transmit signals into the cell. Binding of an extracellular signal protein to the RTK activates its intracellular enzyme (kinase). This process needs to be tightly controlled, as unwanted RTK activation can lead to disease. The discoidin domain receptors, DDR1 and DDR2, are unusual RTKs that are activated by a major structural protein, collagen. Here we show how the enzyme activity of DDR1 is inhibited by a protein segment outside of the kinase domain and how this inhibition is overcome by tyrosine phosphorylation. Our findings reveal an important regulatory mechanism of DDRs and open up avenues for inhibitor design in diseases caused by unwanted DDR signaling.

1 February 2020 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
APAlexander N. Phillipou
Alexander N. Phillipou
CLCharles S. Lay
Charles S. Lay
CCCharlotte E. Carver
Charlotte E. Carver
CMCassie Messenger
Cassie Messenger
JEJohn P. Evans
John P. Evans
PCPeter D. Craggs
Peter D. Craggs
Malfunctions in the basic epigenetic mechanisms such as histone modifications, DNA methylation, and chromatin remodeling are implicated in a number of cancers and immunological and neurodegenerative conditions. Within GlaxoSmithKline (GSK) we have utilized a number of variations of the NanoBRET technology for the direct measurement of compound–target engagement within native cellular environments to drive high-throughput, routine structure–activity relationship (SAR) profiling across differing epigenetic targets. NanoBRET is a variation of the bioluminescence resonance energy transfer (BRET) methodology utilizing proteins of interest fused to either NanoLuc, a small, high-emission-intensity luciferase, or HaloTag, a modified dehalogenase enzyme that can be selectively labeled with a fluorophore. The combination of these two technologies has enabled the application of NanoBRET to biological systems such as epigenetic protein–protein interactions, which have previously been challenging. By synergizing target engagement assays with more complex primary cell phenotypic assays, we have been able to demonstrate compound–target selectivity profiles to enhance cellular potency and offset potential liability risks. Additionally, we have shown that in the absence of a robust, cell phenotypic assay, it is possible to utilize NanoBRET target engagement assays to aid chemistry in progressing at a higher scale than would have otherwise been achievable. The NanoBRET target engagement assays utilized have further shown an excellent correlation with more reductionist biochemical and biophysical assay systems, clearly demonstrating the possibility of using such assay systems at scale, in tandem with, or in preference to, lower-throughput cell phenotypic approaches.

2 May 2023 in Wellcome Open Research
Verified
Journal Article
Open access
MNMuyuan Niu
Muyuan Niu
MMMolly McGrath
Molly McGrath
DSDouglas Sammon
Douglas Sammon
SGScott Gardner
Scott Gardner
RMRhodri Marc Morgan
Rhodri Marc Morgan
EHErhard Hohenester
Erhard Hohenester
Background: Hyaluronic acid (HA) is a major polysaccharide component of the extracellular matrix. HA has essential functions in tissue architecture and the regulation of cell behaviour. HA turnover needs to be finely balanced. Increased HA degradation is associated with cancer, inflammation, and other pathological situations. Transmembrane protein 2 (TMEM2) is a cell surface protein that has been reported to degrade HA into ~5 kDa fragments and play an essential role in systemic HA turnover. Methods: We produced the soluble TMEM2 ectodomain (residues 106-1383; sTMEM2) in human embryonic kidney cells (HEK293) and determined its structure using X-ray crystallography. We tested sTMEM2 hyaluronidase activity using fluorescently labelled HA and size fractionation of reaction products. We tested HA binding in solution and using a glycan microarray. Results: Our crystal structure of sTMEM2 confirms a remarkably accurate prediction by AlphaFold. sTMEM2 contains a parallel β-helix typical of other polysaccharide-degrading enzymes, but an active site cannot be assigned with confidence. A lectin-like domain is inserted into the β-helix and predicted to be functional in carbohydrate binding. A second lectin-like domain at the C-terminus is unlikely to bind carbohydrates. We did not observe HA binding in two assay formats, suggesting a modest affinity at best. Unexpectedly, we were unable to observe any HA degradation by sTMEM2. Our negative results set an upper limit for k cat of approximately 10-5 min-1. Conclusions: Although sTMEM2 contains domain types consistent with its suggested role in TMEM2 degradation, its hyaluronidase activity was undetectable. HA degradation by TMEM2 may require additional proteins and/or localisation at the cell surface.

20 January 2026 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
ZLZhen Li
Zhen Li
HCHimanshi Chawla
Himanshi Chawla
LVLucia Di Vagno
Lucia Di Vagno
ACAisling Ní Cheallaigh
Aisling Ní Cheallaigh
MCMeg Critcher
Meg Critcher
BSBenjamin Schumann
Benjamin Schumann
Mammalian cells receive signaling instructions through interactions on their surfaces. Proteoglycans are critical to these interactions, carrying long glycosaminoglycans that recruit signaling molecules. Biosynthetic redundancy in the first glycosylation step by two xylosyltransferases XT1/2 complicates annotation of proteoglycans. Here we develop a chemical genetic strategy that manipulates the glycan attachment site of cellular proteoglycans. Through a bump-and-hole tactic, we engineer the two isoenzymes XT1 and XT2 to specifically transfer the chemically tagged xylose analog 6AzGlc to target proteins. The tag contains a bioorthogonal functionality, allowing to visualize and profile target proteins in mammalian cells. Unlike xylose analogs, 6AzGlc is amenable to cellular nucleotide-sugar biosynthesis, establishing the XT1/2 bump-and-hole tactic in cells. The approach allows pinpointing glycosylation sites by mass spectrometry and exploiting the chemical handle to manufacture proteoglycans with defined glycosaminoglycan chains for cellular applications. Engineered XT enzymes permit an orthogonal view into proteoglycan biology through conventional techniques in biochemistry.